A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis
American Journal of Nephrology · 2024
DOI: 10.1159/000540227 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Geoffrey A Block und 10 weiteren Autor:innen. Beteiligte Einrichtung: US Renal Care, Plano, Texas, USA. Hauptthemen laut MEDLINE: Ferric Compounds, Renal Dialysis, Hematinics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Introduction
Ferric citrate (FC) is an FDA-approved iron-based phosphate binder for adults with dialysis-dependent chronic kidney disease. This study investigated the impact of FC as the primary phosphate-lowering therapy on utilization of erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron.
Methods
In this randomized, open-label, active-controlled, multicenter study (NCT04922645), patients on dialysis and receiving ESAs were randomized to receive FC or remain on standard of care (SOC) phosphate-lowering therapy for up to 6 months. Primary endpoints were the difference in change from baseline to efficacy evaluation period (EEP) in mean monthly ESA and IV iron doses. Secondary endpoints included treatment differences in hemoglobin, phosphate, TSAT, and ferritin levels.
Results
Two hundred nine patients were randomized to FC and had a day 1 dosing visit (n = 103) or SOC (n = 106). The two groups had similar baseline laboratory characteristics; however, atherosclerotic CV disease, peripheral vascular disease, and congestive heart failure were more common in the SOC group. The mean treatment difference in ESA monthly dose was −30.8 μg (FC vs. SOC; p = 0.02). An absolute though non-statistically significant change in mean monthly IV iron dose of −37.2 mg (p = 0.17) was observed with FC. Mean hemoglobin, TSAT, and ferritin all increased from baseline to the EEP with FC versus SOC. Serious adverse events occurred in 28% of patients receiving FC versus 37% in those receiving SOC.
Conclusions
In patients receiving dialysis, treatment with FC as compared to remaining on SOC phosphate binders resulted in reductions in mean monthly ESA and IV iron dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- US Renal Care, Plano, Texas, USA.
- South Texas Renal Care Group, San Antonio, Texas, USA.
- Nephrology and Hypertension Specialists, PC, Dalton, Georgia, USA.
- High Desert Nephrology Associates, Gallup, New Mexico, USA.
- US Renal Care, Plano, Texas, USA, stephanie.brillhart@usrenalcare.com.
- Outcomes Insights Inc, Calabasas, California, USA.
Zitieren
APA
Block, G. A., Mizani, M. R., Broumand, V., Newby, F. D., Erinle, A., Arias, C., Block, M., Brillhart, S., Leppink, A., Danese, M., & Dittrich, M. (2024). A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis. American Journal of Nephrology. https://doi.org/10.1159/000540227
Vancouver
Block GA, Mizani MR, Broumand V, Newby FD, Erinle A, Arias C, et al. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis. American Journal of Nephrology. 2024. doi:10.1159/000540227
BibTeX
@article{Block2024,
author = {Block, Geoffrey A and Mizani, Mohammed Reza and Broumand, Varshasb and Newby, F David and Erinle, Ayodele and Arias, Carolina and Block, Martha and Brillhart, Stephanie and Leppink, Amanda and Danese, Mark and Dittrich, Mary},
title = {A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis},
journal = {American Journal of Nephrology},
year = {2024},
doi = {10.1159/000540227}
}
EUVIMED